Patent ID: 8647830
Filing Date: 2014-02-11
Classification: G01N

Abstract:
1. An in vitro method for medical diagnosis, prognosis and therapy follow-up for a patient having a cardiac disease or suspected of developing or having a cardiac disease, detecting and quantitating in a sample from said patient at least one marker comprising the midregional area of the amino-terminal portion of pro-atrial natriuretic peptide (proANP [SEQ ID NO:2]) (“NT-pro-ANP”, consisting of amino acids 1-98 of SEQ ID NO:2), said midregional area of pro-ANP (MR-proANP) spanning amino acids 50-90 of SEQ ID NO:2, or partial peptides of NT-proANP, collectively NT-proANP analytes, said analytes having from 12 to 98 amino acids, wherein said detection and quantitation comprises whereby when the amount of bound antibody corresponds to a level of pro-ANP analyte that is higher than a cut-off value of from 190 to 260 pmol/L, as determined in a sample of plasma, and which level is independent of the BMI of the patient, the level of pro-ANP analyte indicates that the patient has or is developing a cardiac disease, wherein attribution of this indication to the patient's clinical picture is used for diagnosis, prognosis or therapeutic follow up of said patient.